Immunology Pipeline
At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines.
Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval.
Copy Page URL
Anti-BLyS (Belimumab)
SABLE: Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Go to ResourceA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) (BE-EARLY)
Go to ResourceB-cell modulator (GSK4527363)
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus Participants and Healthy Chinese and Japanese Participants
Go to ResourceThe Belimumab and Lupus Pregnancy Exposure Study (bMUM): An OTIS Autoimmune Diseases in Pregnancy Project
Go to ResourceLong-acting IL-5 antagonist (depemokimab)
OCEAN: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory EGPA
Go to ResourceAnti-BLyS (Belimumab)
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (BLISSc-ILD)
Go to ResourceAnti-BLyS (Belimumab)
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Go to ResourceAnti-BLyS (Belimumab)
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease (BEconneCTD-ILD)
Go to ResourceA Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Go to ResourceAnti-BLyS (Belimumab)
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN (OBSErve-LN)
Go to ResourceThe Belimumab and Lupus Pregnancy Exposure Study (bMUM)
Go to ResourceUse filter to search Pipeline
Disclaimer
This document contains information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for both approved and investigational compounds.
Some agents are approved in select indications. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov.